Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

642 trials with published results (17%)

Research Maturity

3113 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

168 terminated out of 3875 trials

Success Rate

94.9%

+8.3% vs benchmark

Late-Stage Pipeline

20%

764 trials in Phase 3/4

Results Transparency

21%

642 of 3113 completed with results

Key Signals

642 with results95% success168 terminated

Data Visualizations

Phase Distribution

3,247Total
Not Applicable (971)
Early P 1 (9)
P 1 (862)
P 2 (641)
P 3 (447)
P 4 (317)

Trial Status

Completed3,113
Unknown266
Terminated168
Recruiting117
Withdrawn94
Active Not Recruiting65

Trial Success Rate

94.9%

Benchmark: 86.5%

Based on 3113 completed trials

Clinical Trials (3875)

Showing 20 of 20 trials
NCT06134362Phase 3Active Not RecruitingPrimary

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

NCT02938520Phase 3Active Not RecruitingPrimary

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT07737340RecruitingPrimary

Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)

NCT06679751Active Not RecruitingPrimary

Infectious Disease (ID) Testing OUtreach in Carceral Hubs

NCT06694805Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT05996471Phase 2Active Not RecruitingPrimary

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT03729778Early Phase 1Active Not Recruiting

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT07728123Not ApplicableRecruitingPrimary

Screen2Prevent (S2P)

NCT05388474CompletedPrimary

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

NCT06316739Not ApplicableActive Not RecruitingPrimary

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT03284710Phase 1CompletedPrimary

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

NCT07473778RecruitingPrimary

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT02591420Phase 1CompletedPrimary

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

NCT02447159Not ApplicableCompleted

Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria

NCT07202546Phase 2RecruitingPrimary

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT06317051Phase 3Active Not RecruitingPrimary

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

NCT07682961Phase 3RecruitingPrimary

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07516548Not Yet RecruitingPrimary

Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV

NCT05378399Phase 3CompletedPrimary

SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

NCT05771519Not ApplicableNot Yet RecruitingPrimary

Developing an HIV Disclosure Intervention for Men in Uganda

Scroll to load more

Research Network

Activity Timeline